Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population

Go back to Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population

Moderna (MRNA) Gains, Up 5.5%

March 16, 2021 9:40 AM EDT

Moderna (NASDAQ: MRNA) Gains, Up 5.5%

... More